Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Analysis of adverse events and...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?
Bibliographic Details
Main Authors:
Boyd Kathleen A
,
Briggs Andrew H
,
Paul Jim
,
Iveson Tim
,
Midgely Rachel
,
Harkin Andrea
,
Bates Gaynor
,
Alexander Laura
,
Cassidy Jim
Format:
Article
Language:
English
Published:
BMC
2011-12-01
Series:
Trials
Holdings
Description
Similar Items
Staff View
Similar Items
Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study
by: Paul Jim, et al.
Published: (2011-12-01)
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
by: Kerr, D, et al.
Published: (2007)
Adjuvant chemotherapy for colorectal cancer.
by: Kerr, D, et al.
Published: (1996)
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer
by: Antonia K Roseweir, et al.
Published: (2020-10-01)
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT
by: Timothy Iveson, et al.
Published: (2019-12-01)